Updated: Merck drops $10B for respiratory drugmaker Verona Pharma in its first acquisition of 2025
Merck is boosting its respiratory portfolio with a $10 billion takeover of commercial-stage drugmaker Verona Pharma, the companies said Wednesday morning …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.